Moderna shares rose nearly 20% after Science Day, driven partly by a short squeeze, while its mRNA pipeline beyond vaccines ...

Moderna's flu vaccine may not fuel a further recovery for the hard-hit COVID-19-affected stock.

Moderna expands beyond vaccines while Recursion bets on AI-driven drug discovery, each with distinct risks, partnerships, and ...

Moderna (MRNA) stock jumps on Science Day pipeline update and FDA flu vaccine vote; see key catalysts, technical levels, and ...

Moderna just received fantastic news.

At Science Day, Moderna outlined growth plans across infectious-disease vaccines, Intismeran, and rare-disease therapeutics. ...

At its latest R&D update, Moderna revealed a move into the pioneering in vivo CAR-T category, adding another treatment class ...

Provides broad overview of Company's research and early development programs expected to continue to fuel future ...

Your resource for the hottest moving stocks and news. We cover all sectors and markets giving everyday investors access to ...

Alex Hogan is STAT’s senior multimedia producer and host of STATus Report, STAT’s weekly video series. You can follow him on Bluesky. The story of the biotech company Moderna almost reads like a ...

The company's pending vaccine approvals could help the stock continue its rise.

CNBC's Jim Cramer talks about his take on Moderna's stock performance and business outlook.